Tear Sheet

Company Overview

HTG’s mission is to advance the promise of precision medicine through innovative transcriptome-wide profiling technology designed to accelerate the development of diagnostics and hasten the discovery of novel drug candidates to effect lifechanging outcomes. Building on more than a decade of pioneering innovation and partnerships with biopharma leaders and major academic institutes, HTG’s proprietary RNA platform technologies are designed to make the development of life science tools and diagnostics more effective and efficient and to unlock a differentiated and disruptive approach to transformative drug discovery. 

Events

Stock Quote

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics to Participate in the Cantor Fitzgerald Oncology, Hematology & HemeOnc Conference
TUCSON, Ariz. , Sept. 26, 2022 (GLOBE NEWSWIRE) --  HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that management will participate in the Cantor Fitzgerald
Toggle Summary The Fundación Instituto Valenciano de Oncología Leverages HTG Technology for Breast Cancer Laboratory-Developed Test
TUCSON, Ariz. , Sept. 20, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, announced that the Fundación Instituto Valenciano de Oncología, located in
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2022 Results
Call scheduled for today, August 11, 2022, at 4:30 pm ET TUCSON, Ariz. , Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent
Toggle Summary HTG Molecular Diagnostics to Announce Q2 2022 Financial Results and Host Conference Call on Thursday, August 11
TUCSON, Ariz. , Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended
Toggle Summary HTG Molecular Diagnostics Hosting a KOL Event Addressing Drug Candidate Attrition
TUCSON, Ariz. , July 19, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will host a key opinion leader (KOL) webinar on “ Drug

Stock Chart

SEC Filings

Filing date Description

Report of unscheduled material events or corporate event

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities